@article{oai:nagasaki-u.repo.nii.ac.jp:00011538,
 author = {Itonaga, Hidehiro and Tsushima, Hideki and Hata, Tomoko and Matsuo, Emi and Imanishi, Daisuke and Imaizumi, Yoshitaka and Kawaguchi, Yasuhisa and Fukushima, Takuya and Doi, Yuko and Mori, Sayaka and Kamihira, Shimeru and Tomonaga, Masao and Miyazaki, Yasushi},
 issue = {2},
 journal = {International Journal of Hematology},
 month = {Feb},
 note = {The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation., International Journal of Hematology, 95(2), pp.209-213; 2012},
 pages = {209--213},
 title = {Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa},
 volume = {95},
 year = {2012}
}